Abstracts tagged "SLE"

Abstract Number: 25 • 2013 ACR/ARHP Annual Meeting
SLE Flares Are Characterized By Generalized Polyclonal Expansions Of Antibody Secreting Cells Without Preference For Autoimmune Responses
H. Travis Ichikawa, Medicine, Emory University, Atlanta, GA
Background/Purpose: Increased circulating antibody secreting cells (ASC), including both CD138- plasmablasts and CD138+ plasma cells (PB/PC), correlate with SLE activity and are prominent during Lupus…
Abstract Number: 2796 • 2013 ACR/ARHP Annual Meeting
Effects Of BAFF Inhibition On B Cell Selection In Murine SLE
Alexis Boneparth^1,2, Ramalingam Bethunaickan³, Weiqing Huang⁴ and Anne Davidson⁴, ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Feinstein Institute for medical Research, Manhasset, NY, ³Autoimmunity, Feinstein Institute for Medical Research, Manhasset, NY, ⁴Autoimmunity and Musculoskeletal Diseases, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: BAFF inhibition is a new B cell targeted therapy approved for the treatment of moderately active SLE. Although BAFF regulates selection of naïve autoreactive…
Abstract Number: 1646 • 2013 ACR/ARHP Annual Meeting
Alterations In Circulating T Follicular Helper Cells and T Regulatory Cells In Autoimmune Rheumatic Diseases Treated With B Cell Depletion Therapy: Rituximab
Pamela M.K Lutalo^1,2, Yuan Zhao², Lee Meng Choong¹, Shirish Sangle¹, Jo Spencer³ and David P. D'Cruz⁴, ¹Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom, ²Peter Gorer Department of Immunobiology, School of Medicine, King's College London, London, United Kingdom, ³Peter Gorer Department of Immunobiology, King's College London, School of Medicine, London, United Kingdom, ⁴Louise Coote Lupus Unit, Louise Coote Lupus Unit, St Thomas' Hospital, London, United Kingdom
Background/Purpose: Granulomatosis with polyangiitis (GPA) and systemic lupus erythematosus (SLE) are autoimmune rheumatic diseases which develop due to failure of immune self-tolerance. T follicular helper…
Abstract Number: 1571 • 2013 ACR/ARHP Annual Meeting
Efficacy Of Tacrolimus Combination Therapy During The Maintenance Phase Of Systemic Lupus Erythematosus
Kumiko Ohtsuka¹, Yusuke Miwa¹, Nao Oguro², Yoko Miura¹, Sho Ishii¹, Shinya Seki¹, Hidekazu Furuya¹, Ryo Yanai¹, Ryo Takahashi¹, Kuninobu Wakabayashi¹, Nobuyuki Yajima¹ and Tsuyoshi Kasama¹, ¹Div of Rheumatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan, ²Div of Rhemuatology, Showa University School of Med, Shinagawa-ku Tokyo, Japan
Background/Purpose: In Japan, a placebo-controlled clinical trial was undertaken to investigate the efficacy and safety of tacrolimus (TAC) for lupus nephritis. Based on the results…
Abstract Number: 637 • 2013 ACR/ARHP Annual Meeting
Proteomic Approach and Validation Of Urinary Biomarkers In Lupus Nephritis
Joo Youn Lee¹, Sung Hae Chang², Hye Jin Oh³, Yong Yook Lee¹, Min Jueng Kang¹, Eun Young Lee⁴, Eun Bong Lee⁵, Eugene C. Yi¹ and Young Wook Song^1,5, ¹Department of Molecular Medicine and Biopharmaceutical Sciences, Seoul National University, Seoul, South Korea, ²Internal Medicine Rheumatology, Seoul National University Bundang Hospital, Seongnam-si, South Korea, ³Seoul National University, Seoul, South Korea, ⁴Internal medicine, Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea, ⁵Division of Rheumatology, Department of Internal Medicine, Seoul National University, Seoul, South Korea
Background/Purpose: Renal involvement occurs in about half of systemic lupus erythematosus (SLE) patients. A number of biochemical markers are currently used to clinically assess lupus…
Abstract Number: 31 • 2013 ACR/ARHP Annual Meeting
IgD- CD27- B Cells From Systemic Lupus Erythematous Patients Have Increased Expression Of Genes Involved In RNA Sensing and Toll-Like Receptor 3 Signaling Pathways
Scott Jenks¹, Edward Ramos² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Biology, Emory University, Atlanta, GA, ³Allergy, Immunology and Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: SLE patients have perturbations in B cell subsets including a large expansion of IgD-CD27- B cells (DN) in patients with active disease. Patients also…
Abstract Number: 2797 • 2013 ACR/ARHP Annual Meeting
B-Lymphocyte Stimulator and A Proliferation Inducing Ligand In Lupus Nephritis: Low Serum Levels Of BLyS Predict Treatment Response
Ioannis Parodis¹, Agneta Zickert¹, Elisabet Svenungsson², Vivianne Malmström² and Iva Gunnarsson¹, ¹Department of Medicine, Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, ²Rheumatology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: B-lymphocytes have a pivotal role in the pathogenesis of Systemic Lupus Erythematosus (SLE). B-Lymphocyte Stimulator (BLyS) has an important role in the activation, differentiation…
Abstract Number: 1630 • 2013 ACR/ARHP Annual Meeting
Association Of TREM-Like Transcript-1 With Systemic Lupus Erythematosus
Yerania Rodríguez-Navedo¹, Karina Vilá -Rivera¹, Mariely Nieves-Plaza², Martha Ricaurte³, A. Valance Washington³ and Luis M. Vilá¹, ¹Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, ²University of Pittsburgh, Pittsburgh, PA, ³University of Puerto Rico, Río Piedras Campus, San Juan, PR
Background/Purpose: Recent studies suggest that a platelet α-granule protein named TREM-like transcript-1 (TLT-1) is a key molecule in modulating the inflammatory response. TLT-1 has been…
Abstract Number: 1572 • 2013 ACR/ARHP Annual Meeting
High Type I Interferon In Systemic Lupus Erythematosus Plasma Predicts Future Renal Disease
Kyriakos A. Kirou¹, Mikhail Olferiev¹, Elzbieta E. Jacek¹, Mari Lliguicota¹, Margaret Robotham¹, Wei-Ti Huang², Elena Gkrouzman¹ and Mary K. Crow³, ¹Hospital for Special Surgery, New York, NY, ²Biostatistics, Hospital for Special Surgery, New York, NY, ³Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Type I interferon (IFN-I) is elevated in many patients with SLE and is associated with more severe disease. However, the relationship between elevated levels…
Abstract Number: 640 • 2013 ACR/ARHP Annual Meeting
Systemic Lupus Erythematosus Patients With Atherosclerosis Are Characterised By a Distinct Invariant Natural Killer T Cell Phenotype and Altered CD1d-Mediated Lipid Antigen Presentation
Edward Smith¹, Sara Croca², Andrew Pitcher¹, D.A. Isenberg¹, Anisur Rahman³ and Elizabeth C. Jury⁴, ¹Centre for Rheumatology Research, University College London, London, United Kingdom, ²Centre for Rheumatology Research, Division of Medicine, University College London, London, United Kingdom, ³Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁴Division of Medicine, Centre for Rheumatology Research, University College London, London, United Kingdom
Background/Purpose: It is widely reported that systemic lupus erythematosus (SLE) patients have an increased risk of atherosclerosis compared to the general population, irrespective of traditional…
Abstract Number: 32 • 2013 ACR/ARHP Annual Meeting
Understanding The Stimulatory Pathways Responsible For Naïve B Cell Activation In Systemic Lupus Erythematosus
Emily Blalock¹, Chris Scharer², Scott Jenks¹, Jeremy Boss² and Ignacio Sanz³, ¹Allergy, Immunology, and Rheumatology, Emory University School of Medicine, Atlanta, GA, ²Microbiology and Immunology, Emory University School of Medicine, Atlanta, GA, ³Allergy, Immunology and Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Systemic lupus erythematosus (SLE) is a recurrent autoimmune disease characterized by multiple B cell abnormalities, including the activation of naïve B cells. However, gaps…
Abstract Number: 2737 • 2013 ACR/ARHP Annual Meeting
In Vivo MiR-146a Administration Ameliorates Murine Lupus Nephritis
Dong Liang¹, Shiyu Zhou², Zheng Liu³, Zhengyuan Shan¹, Philip Brohawn³, Yihong Yao³, Indu Raman⁴, Quan-Zhen Li⁴, John B. Harley^5,6 and Nan Shen^1,2,7, ¹Division of Rheumatology & the Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Shanghai Institutes for Biological Sciences Chinese Academy of Sciences & Shanghai Jiao Tong University School of Medicine, Shanghai, China, ³Translational Sciences, MedImmune, LLC, Gaithersburg, MD, ⁴Department of Immunology and Microarray Core Facility, University of Texas Southwestern Medical Center, Dallas, TX, ⁵Division of Rheumatology and The Center for Autoimmune Genomics & Etiology, University of Cincinnati, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁶US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁷Shanghai Institute of Rheumatology, Shanghai Institute of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China
Background/Purpose: New Zealand black and white F1 (NZBW/F1) is a classic mouse model of systemic lupus erythematosus (SLE). Type I interferon (IFN) infusion accelerates lupus…
Abstract Number: 1631 • 2013 ACR/ARHP Annual Meeting
Transcription Activation-Like Effector Nuclease-Mediated Enhancer Knockout Influences TNFAIP3 Gene Expression and Mimics a Functional Phenotype Associated With Systemic Lupus Erythematosus
Shaofeng Wang¹, Feng Wen², Bo He³ and Patrick M. Gaffney⁴, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Pathology, The University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: Emerging technologies for precise, targeted genome editing provide new opportunities for the functional elucidation of causal genetic variants and genomic elements without the confounding…
Abstract Number: 1581 • 2013 ACR/ARHP Annual Meeting
Lipid Lowering Medication Use Is Associated With Reduced Muscle Strength In Systemic Lupus Erythematosus
James S. Andrews¹ and Patricia P. Katz², ¹Rheumatology, University of California San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA
Background/Purpose: Premature atherosclerotic coronary artery disease is a major source of morbidity for women with systemic lupus erythematosus (SLE). Lipid lowering medications (LLM) are among…
Abstract Number: 604 • 2013 ACR/ARHP Annual Meeting
Mycophenolate Mofetil Is Not Associated With Reduced Cardiovascular Or Lupus Damage Accumulation In a Cross-Sectional Lupus Cohort Study
Maureen A. McMahon¹, Maria Dall'era², Eliza Chakravarty³, Joseph E. Craft⁴, Gary S. Gilkeson⁵, Kenneth C. Kalunian⁶, R. John Looney⁷, Gerald McGwin Jr.⁸ and Meggan Mackay⁹, ¹Division of Rheumatology, UCLA David Geffen School of Medicine, Los Angeles, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Yale University School of Medicine, Internal Medicine, Section of Rheumatology, New Haven, CT, ⁵Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁶UCSD School of Medicine, La Jolla, CA, ⁷Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ⁸Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁹Autoimmune & Musculoskeletal Disease, Feinstein Institute for Medical Research, Manhasset, NY
Background/Purpose: Mycophenolate mofetil (MMF) is frequently used for the treatment of lupus. The immune-modulating effects of MMF extend beyond effects on lymphocyte proliferation, and include…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].